Maxygen First Quarter 2008 Financial Results Conference Call Notice

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY) will host a conference call to discuss the company’s first quarter 2008 financial results at 11:30 a.m. ET (8:30 a.m. PT) on Tuesday, May 6, 2008. Russell Howard, Maxygen’s chief executive officer, will host the call. A press release announcing Maxygen’s first quarter 2008 financial results will be issued earlier that same day at approximately 9:00 a.m. ET (6:00 a.m. PT).

Participants in the U.S. can access the call by dialing 866.700.7173 and using the passcode 79178894. International participants can dial 617.213.8838 and use the same passcode. A live webcast of the conference call will be available on the Maxygen web site at www.maxygen.com/webcasts.

Telephone and webcast replays of the conference call will be available until June 6, 2008. To access the telephone replay, dial 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 75305350. To access the webcast archive, go to www.maxygen.com/webcasts.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company’s lead program, MAXY-G34, is designed to be an improved version of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen’s pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. www.maxygen.com